Your browser doesn't support javascript.
loading
A 5-year clinical follow-up study from the Italian National Registry for FSHD.
Vercelli, Liliana; Mele, Fabiano; Ruggiero, Lucia; Sera, Francesco; Tripodi, Silvia; Ricci, Giulia; Vallarola, Antonio; Villa, Luisa; Govi, Monica; Maranda, Louise; Di Muzio, Antonio; Scarlato, Marina; Bucci, Elisabetta; Maggi, Lorenzo; Rodolico, Carmelo; Moggio, Maurizio; Filosto, Massimiliano; Antonini, Giovanni; Previtali, Stefano; Angelini, Corrado; Berardinelli, Angela; Pegoraro, Elena; Siciliano, Gabriele; Tomelleri, Giuliano; Santoro, Lucio; Mongini, Tiziana; Tupler, Rossella.
Afiliação
  • Vercelli L; Department of Neurosciences "Rita Levi Montalcini", Center for Neuromuscular Diseases, University of Turin, Turin, Italy.
  • Mele F; Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Ruggiero L; Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy.
  • Sera F; Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine, London, UK.
  • Tripodi S; Department of Neurosciences, University of Padua, Padua, Italy.
  • Ricci G; Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Vallarola A; Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
  • Villa L; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, via G. Campi 287, 41125, Modena, Italy.
  • Govi M; Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy.
  • Maranda L; Neuromuscular Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, University of Milan, Milan, Italy.
  • Di Muzio A; Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Scarlato M; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, USA.
  • Bucci E; Center for Neuromuscular Disease, CeSI, University "G. D'Annunzio", Chieti, Italy.
  • Maggi L; INSPE and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Rodolico C; Department of Neuroscience, Mental Health and Sensory Organs, S. Andrea Hospital, University of Rome "La Sapienza", Rome, Italy.
  • Moggio M; IRCCS Foundation, C. Besta Neurological Institute, Milan, Italy.
  • Filosto M; Department of Neurosciences, Policlinico "G. Martino", University of Messina, Messina, Italy.
  • Antonini G; Neuromuscular Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, University of Milan, Milan, Italy.
  • Previtali S; Neurology Clinic, Spedali Civili Hospital, Brescia, Italy.
  • Angelini C; Department of Neuroscience, Mental Health and Sensory Organs, S. Andrea Hospital, University of Rome "La Sapienza", Rome, Italy.
  • Berardinelli A; INSPE and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Pegoraro E; IRCCS San Camillo, Venice, Italy.
  • Siciliano G; Unit of Child Neurology and Psychiatry, IRCCS "C. Mondino" Foundation, Pavia, Italy.
  • Tomelleri G; Department of Neurosciences, University of Padua, Padua, Italy.
  • Santoro L; Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
  • Mongini T; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, via G. Campi 287, 41125, Modena, Italy.
  • Tupler R; Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy.
J Neurol ; 268(1): 356-366, 2021 Jan.
Article em En | MEDLINE | ID: mdl-32813049
BACKGROUND: The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined. METHODS: An observational cohort study was conducted in 246 FSHD1 patients. We split the analysis between index cases and carrier relatives and we classified all patients using the Comprehensive Clinical Evaluation Form (CCEF). The disease progression was measured as a variation of the FSHD score performed at baseline and at the end of 5-year follow-up (ΔFSHD score). FINDINGS: Disease worsened in 79.4% (112/141) of index cases versus 38.1% (40/105) of carrier relatives and advanced more rapidly in index cases (ΔFSHD score 2.3 versus 1.2). The 79.1% (38/48) of asymptomatic carriers remained asymptomatic. The highest ΔFSHD score (1.7) was found in subject with facial and scapular weakness at baseline (category A), whereas in subjects with incomplete phenotype (facial or scapular weakness, category B) had lower ΔFSHD score (0.6) p < 0.0001. CONCLUSIONS: The progression of disease is different between index cases and carrier relatives and the assessment of the CCEF categories has strong prognostic effect in FSHD1 patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Distrofia Muscular Facioescapuloumeral Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Neurol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Distrofia Muscular Facioescapuloumeral Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Neurol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália